Details of Disease

General Information of Disease (ID: DISELRCI)

• Disease Name: Myasthenia gravis
• Synonyms: MG; autoimmune myasthenia gravis; acquired myasthenia; myasthenia gravis
• Disease Class: 8C6Y: Myasthenia gravis
• Definition: Myasthenia gravis (MG) is a rare, clinically heterogeneous, autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles.
• Disease Hierarchy:
  DISAE4AP: Autoimmune disorder of peripheral nervous system
  DISELRCI: Myasthenia gravis
• ICD Code: ICD-11: ICD-11: 8C6Y
• Disease Identifiers:
  MONDO ID: MONDO_0009688
  MESH ID: D009157
  UMLS CUI: C0026896
  OMIM ID: 254200
  MedGen ID: 7764
  Orphanet ID: 589
  SNOMED CT ID: 91637004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ambenonium	DMOP0BL	Approved	Small molecular drug	[1]
Edrophonium	DMCRQHB	Approved	Small molecular drug	[2]
Efgartigimod alfa	DM2M93X	Approved	NA	[3]
Methylphenidate	DM7SJD6	Approved	Small molecular drug	[4]
Neostigmine	DM6T2J3	Approved	Small molecular drug	[5]
Pyridostigmine	DM8HO1L	Approved	Small molecular drug	[6]
Rozanolixizumab	DMK0NGB	Approved	NA	[7]
Zilucoplan	DM9Z4N5	Approved	NA	[8]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ARGX-113	DM180DM	Phase 3	Small molecular drug	[9]
Batoclimab	DMYPMR8	Phase 3	Monoclonal antibody	[10]
BQ788	DM6KRLW	Phase 3	Small molecular drug	[11]
BVT.2733	DM6RUKX	Phase 3	Small molecular drug	[11]
Nipocalimab	DM0622O	Phase 3	Monoclonal antibody	[12]
CFZ533	DM1TWIE	Phase 2	NA	[11]
Gamunex-C	DM8U7FG	Phase 2	NA	[11]
Mezagitamab	DMWJXFO	Phase 2	Monoclonal antibody	[13]
ACT-101	DMQW7LR	Phase 1	NA	[7]
GTP-004	DM20HS7	Phase 1	NA	[7]

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BHT-3034	DMZRS7A	Investigative	NA	[14]
CuraVac MG	DMTOJES	Investigative	NA	[15]
D17.4	DMSON1P	Investigative	Aptamer	[16]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 41 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CA3	TTXUK5D	Limited	Biomarker	[17]
CACNA1S	TT94HRF	Limited	Biomarker	[18]
CCL21	TTLZK1U	Limited	Biomarker	[19]
CCR9	TTIPS8B	Limited	Altered Expression	[20]
CD83	TTT9MRQ	Limited	Biomarker	[21]
CHRNA4	TT4H1MQ	Limited	Biomarker	[22]
CLEC4C	TT7YT06	Limited	Biomarker	[23]
CNTFR	TTT2F9E	Limited	Altered Expression	[24]
CR2	TT0HUN7	Limited	Biomarker	[25]
CTSV	TTSD9T1	Limited	Genetic Variation	[26]
CXCL13	TT0NIZ1	Limited	Altered Expression	[27]
GRIA2	TTWM461	Limited	Biomarker	[28]
GRM2	TTXJ47W	Limited	Biomarker	[28]
HLA-A	TTHONFT	Limited	Biomarker	[29]
ICOSLG	TTB9Z8R	Limited	Biomarker	[30]
IL12RB2	TT4SWR8	Limited	Genetic Variation	[31]
IL2RA	TT10Y9E	Limited	Biomarker	[32]
MBP	TT2RY5P	Limited	Biomarker	[33]
SCN4A	TT84DRB	Limited	Genetic Variation	[34]
SGCA	TTS9Q5V	Limited	Genetic Variation	[35]
TEC	TT1ZV49	Limited	Biomarker	[36]
TNFRSF25	TTDV6BQ	Limited	Altered Expression	[37]
CFB	TTA0P7K	Disputed	Genetic Variation	[38]
MUSK	TT6SA0X	moderate	Biomarker	[39]
ACHE	TT1RS9F	Strong	Biomarker	[40]
BCHE	TT3MSAO	Strong	Biomarker	[40]
CYP21A2	TTP4GLG	Strong	Genetic Variation	[38]
FAS	TT7LTUJ	Strong	Biomarker	[41]
GNAO1	TTAXD8Z	Strong	Biomarker	[42]
HLA-B	TTGS10J	Strong	Biomarker	[43]
HLA-DQB2	TTL7VOU	Strong	Biomarker	[42]
IL21	TT9QEJ6	Strong	Biomarker	[44]
NOTCH4	TTXDIK2	Strong	Genetic Variation	[38]
PDCD1	TTNBFWK	Strong	Biomarker	[45]
POMC	TT21AKM	Strong	Therapeutic	[46]
SMN1	TT8QL6X	Strong	Biomarker	[47]
TLR9	TTSHG0T	Strong	Biomarker	[48]
TNFRSF11A	TT3K9S2	Strong	Genetic Variation	[49]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[50]
TSLP	TTHMW3T	Strong	Biomarker	[51]
TNFRSF17	TTZ3P4W	Definitive	Altered Expression	[52]

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC6	DT582KR	Limited	Genetic Variation	[53]
SLC25A37	DTLBGTZ	Limited	Biomarker	[54]
SLC7A9	DTP7AEQ	Limited	Genetic Variation	[55]

This Disease Is Related to 65 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BRINP1	OTEUVSCP	Limited	Biomarker	[56]
C4A	OTXMOYXU	Limited	Genetic Variation	[55]
CCAR2	OTLUDG5T	Limited	Biomarker	[56]
CDIPT	OTZX703K	Limited	Genetic Variation	[57]
CDS1	OT2F591M	Limited	Genetic Variation	[58]
CHRND	OTLUUP7C	Limited	Genetic Variation	[59]
CLC	OTYMYR85	Limited	Altered Expression	[60]
DDX39A	OT0Z6E1K	Limited	Genetic Variation	[55]
DDX39B	OTEVCFVU	Limited	Genetic Variation	[55]
DIPK1A	OTWS5V2I	Limited	Biomarker	[61]
DOK7	OTR2V7HO	Limited	Altered Expression	[62]
DPYSL5	OT6F9T6F	Limited	Biomarker	[63]
ECD	OT3L3PCU	Limited	Biomarker	[64]
FAM136A	OT9WY5AH	Limited	Biomarker	[61]
FHDC1	OTMMV8ZN	Limited	Altered Expression	[65]
HIF3A	OTPWAAMC	Limited	Altered Expression	[66]
HLA-DPA1	OT7OG7Y2	Limited	Biomarker	[29]
HLA-DRB3	OT5PM9N7	Limited	Genetic Variation	[67]
IFNA17	OTHXRYG3	Limited	Biomarker	[68]
IFNGR1	OTCTQBWW	Limited	Biomarker	[69]
ISG20	OTCWRJJW	Limited	Biomarker	[32]
LGALS8	OT71LJ8T	Limited	Genetic Variation	[70]
LGI1	OTPS77HO	Limited	Biomarker	[71]
MSL2	OTVPQYBG	Limited	Altered Expression	[72]
MYOG	OTPLJKFA	Limited	Biomarker	[73]
PAX7	OTDMQRPO	Limited	Biomarker	[74]
PPP1R15A	OTYG179K	Limited	Altered Expression	[60]
PPP6R2	OTERHESI	Limited	Altered Expression	[61]
PRSS16	OTVCZ5V1	Limited	Biomarker	[75]
RELB	OTU3QYEF	Limited	Altered Expression	[60]
SLAMF1	OTBTT3ZQ	Limited	Biomarker	[18]
TMEM109	OTLUUDH1	Limited	Biomarker	[76]
TRIM9	OTKYG33W	Limited	Biomarker	[77]
SCO1	OTC45UGB	moderate	Genetic Variation	[78]
ABCF1	OT6Q079J	Strong	Genetic Variation	[38]
ATP6V1G2	OTM1DSKL	Strong	Genetic Variation	[49]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[38]
C2	OTHMF4YM	Strong	Altered Expression	[79]
C4orf3	OT6TFN1O	Strong	Biomarker	[80]
CAV3	OTWSFDB4	Strong	Altered Expression	[81]
GABBR1	OTU5A52J	Strong	Genetic Variation	[38]
GPANK1	OT1TN2KT	Strong	Genetic Variation	[38]
GPSM3	OT2MO458	Strong	Genetic Variation	[38]
HLA-DQA2	OT1DH0N9	Strong	Genetic Variation	[38]
MICB	OTS2DVDW	Strong	Genetic Variation	[38]
MSH5	OTDARQT3	Strong	Genetic Variation	[38]
MUC21	OTQ8GP5L	Strong	Genetic Variation	[38]
MUCL3	OTGAD3I0	Strong	Genetic Variation	[38]
NFKBIL1	OTYFTPS0	Strong	Genetic Variation	[49]
PDLIM7	OTAZVODU	Strong	Biomarker	[82]
POU5F1	OTDHHN7O	Strong	Genetic Variation	[38]
PRRC2A	OTBX6FM5	Strong	Genetic Variation	[38]
PSORS1C1	OT9HK436	Strong	Genetic Variation	[38]
PTPN22	OTDCNTC3	Strong	Genetic Variation	[83]
RBBP8	OTRHJ3GI	Strong	Genetic Variation	[49]
RNF39	OTUQA9JT	Strong	Genetic Variation	[38]
SEMA5A	OTUOIOJV	Strong	Genetic Variation	[49]
SFTA2	OTVRIUIV	Strong	Genetic Variation	[38]
STK19	OTYM6437	Strong	Genetic Variation	[38]
TCF19	OT7NKLF9	Strong	Genetic Variation	[38]
TRIM31	OT7VW6RP	Strong	Genetic Variation	[38]
TSBP1	OT5GE8IO	Strong	Genetic Variation	[38]
TTN	OT0LZ058	Strong	Biomarker	[84]
HLA-DQB1	OTVVI3UI	Definitive	Genetic Variation	[42]
TNIP1	OTRAOTEW	Definitive	Genetic Variation	[85]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010155.
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040131.
• [3] FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761195.
• [4] Methylphenidate FDA Label
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040457.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT04225871) Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT). U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03770403) A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+). U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT05403541) A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG). U.S.National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] ClinicalTrials.gov (NCT04951622) Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
• [13] ClinicalTrials.gov (NCT04159805) A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
• [15] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [16] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
• [17] Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis.Autophagy. 2017;13(11):1981-1994. doi: 10.1080/15548627.2017.1375633. Epub 2017 Sep 29.
• [18] Whole-genome analysis in Korean patients with autoimmune myasthenia gravis.Yonsei Med J. 2014 May;55(3):660-8. doi: 10.3349/ymj.2014.55.3.660. Epub 2014 Apr 1.
• [19] Analysis of microRNA expression in the thymus of Myasthenia Gravis patients opens new research avenues.Autoimmun Rev. 2018 Jun;17(6):588-600. doi: 10.1016/j.autrev.2018.01.008. Epub 2018 Apr 13.
• [20] CCR9 AND CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients.Muscle Nerve. 2017 Jan;55(1):84-90. doi: 10.1002/mus.24999. Epub 2016 Oct 24.
• [21] Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis.Muscle Nerve. 2003 May;27(5):582-9. doi: 10.1002/mus.10362.
• [22] Analysis of peripheral B cells and autoantibodies against the anti-nicotinic acetylcholine receptor derived from patients with myasthenia gravis using single-cell manipulation tools.PLoS One. 2017 Oct 17;12(10):e0185976. doi: 10.1371/journal.pone.0185976. eCollection 2017.
• [23] Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus.Ann Neurol. 2010 Jun;67(6):726-38. doi: 10.1002/ana.21902.
• [24] Expression of ciliary neurotrophic factor receptor in myasthenia gravis.J Neuroimmunol. 2001 Nov 1;120(1-2):180-9. doi: 10.1016/s0165-5728(01)00423-4.
• [25] The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis.J Neuroimmunol. 2013 Mar 15;256(1-2):49-54. doi: 10.1016/j.jneuroim.2012.11.003. Epub 2012 Dec 23.
• [26] Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis.Hum Immunol. 2007 Sep;68(9):748-55. doi: 10.1016/j.humimm.2007.05.009. Epub 2007 Jun 28.
• [27] Micro-RNA-143 inhibits proliferation and promotes apoptosis of thymocytes by targeting CXCL13 in a myasthenia gravis mouse model.Am J Physiol Cell Physiol. 2019 Jan 1;316(1):C70-C80. doi: 10.1152/ajpcell.00090.2018. Epub 2018 Nov 7.
• [28] Anti--amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor GluR2 encephalitis in a myasthenia gravis patient with complete thymectomy: a case report.BMC Neurol. 2019 Jun 13;19(1):126. doi: 10.1186/s12883-019-1358-7.
• [29] HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients.J Clin Neurosci. 2019 Jan;59:179-184. doi: 10.1016/j.jocn.2018.10.077. Epub 2018 Oct 24.
• [30] Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.Clin Immunol. 2019 Oct;207:68-78. doi: 10.1016/j.clim.2019.07.011. Epub 2019 Jul 30.
• [31] Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?.J Neuroimmunol. 2018 Jun 15;319:93-99. doi: 10.1016/j.jneuroim.2018.03.008. Epub 2018 Mar 17.
• [32] Regulatory T cells in multiple sclerosis and myasthenia gravis.J Neuroinflammation. 2017 Jun 9;14(1):117. doi: 10.1186/s12974-017-0892-8.
• [33] Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.Ann Neurol. 1994 Feb;35(2):197-203. doi: 10.1002/ana.410350211.
• [34] A sodium channel myotonia due to a novel SCN4A mutation accompanied by acquired autoimmune myasthenia gravis.Neurosci Lett. 2012 Jun 21;519(1):67-72. doi: 10.1016/j.neulet.2012.05.023. Epub 2012 May 14.
• [35] Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale.Muscle Nerve. 2019 May;59(5):583-586. doi: 10.1002/mus.26435. Epub 2019 Feb 12.
• [36] Functional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymomas from myasthenia gravis patients.J Immunol. 1999 Feb 15;162(4):2103-12.
• [37] Genetic characterization of thymoma.Sci Rep. 2019 Feb 20;9(1):2369. doi: 10.1038/s41598-019-38878-z.
• [38] Risk for myasthenia gravis maps to a (151) ProAla change in TNIP1 and to human leukocyte antigen-B*08.Ann Neurol. 2012 Dec;72(6):927-35. doi: 10.1002/ana.23691. Epub 2012 Oct 10.
• [39] Roles of collagen Q in MuSK antibody-positive myasthenia gravis.Chem Biol Interact. 2016 Nov 25;259(Pt B):266-270. doi: 10.1016/j.cbi.2016.04.019. Epub 2016 Apr 24.
• [40] Sustainable Effects of Distigmine Bromide on Urinary Bladder Contractile Function.Pharmacology. 2020;105(3-4):135-144. doi: 10.1159/000503453. Epub 2019 Oct 15.
• [41] [The relationship between abnormal apoptosis and Fas expression of thymocytes from patients with myasthenia gravis].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Sep;19(5):450-3.
• [42] Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.J Neurol. 2019 Apr;266(4):982-989. doi: 10.1007/s00415-019-09225-z. Epub 2019 Feb 11.
• [43] Novel genetic loci associated HLA-B*08:01 positive myasthenia gravis.J Autoimmun. 2018 Mar;88:43-49. doi: 10.1016/j.jaut.2017.10.002. Epub 2017 Oct 14.
• [44] Effects of Follicular Helper T Cells and Inflammatory Cytokines on Myasthenia Gravis.Curr Mol Med. 2019;19(10):739-745. doi: 10.2174/1566524019666190827162615.
• [45] Myasthenia gravis induced by avelumab.Immunotherapy. 2019 Oct;11(14):1181-1185. doi: 10.2217/imt-2019-0106. Epub 2019 Aug 29.
• [46] Treatment of ocular myasthenia with corticotrophin.J Neurol Neurosurg Psychiatry. 1971 Feb;34(1):11-3. doi: 10.1136/jnnp.34.1.11.
• [47] Double trouble: spinal muscular atrophy type II and seropositive myasthenia gravis in the same patient.Neuromuscul Disord. 2012 Feb;22(2):129-30. doi: 10.1016/j.nmd.2011.07.011. Epub 2011 Aug 20.
• [48] Toll-like receptor 9 antagonist suppresses humoral immunity in experimental autoimmune myasthenia gravis.Mol Immunol. 2018 Feb;94:200-208. doi: 10.1016/j.molimm.2018.01.005. Epub 2018 Jan 12.
• [49] Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.Mol Med. 2016 Mar;21(1):769-781. doi: 10.2119/molmed.2015.00232. Epub 2015 Nov 10.
• [50] High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model.Clin Immunol. 2017 Mar;176:122-130. doi: 10.1016/j.clim.2017.01.005. Epub 2017 Jan 15.
• [51] Elevated expression of interleukin-33 in myasthenia gravis patients.J Clin Neurosci. 2019 May;63:32-36. doi: 10.1016/j.jocn.2019.02.012. Epub 2019 Mar 1.
• [52] The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis.Scand J Immunol. 2007 May;65(5):461-6. doi: 10.1111/j.1365-3083.2007.01921.x.
• [53] A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravis.Pharmacogenet Genomics. 2017 Feb;27(2):51-56. doi: 10.1097/FPC.0000000000000257.
• [54] Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.JCI Insight. 2017 Apr 6;2(7):e89665. doi: 10.1172/jci.insight.89665.
• [55] Ancestral haplotypes carry haplotypic and haplospecific polymorphisms of BAT1: possible relevance to autoimmune disease.Eur J Immunogenet. 1992 Jun;19(3):121-7. doi: 10.1111/j.1744-313x.1992.tb00051.x.
• [56] DBC1 is a suppressor of B cell activation by negatively regulating alternative NF-B transcriptional activity.J Immunol. 2014 Dec 1;193(11):5515-24. doi: 10.4049/jimmunol.1401798. Epub 2014 Oct 31.
• [57] Rituximab as induction therapy in refractory myasthenia gravis: 18month follow-up study.J Neurol. 2019 Jul;266(7):1596-1600. doi: 10.1007/s00415-019-09296-y. Epub 2019 Mar 27.
• [58] CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis.Genes Immun. 2002 Feb;3(1):46-9. doi: 10.1038/sj.gene.6363816.
• [59] Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis.Genes Immun. 2004 Jan;5(1):80-3. doi: 10.1038/sj.gene.6364041.
• [60] A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients.Immunobiology. 2016 Nov;221(11):1227-36. doi: 10.1016/j.imbio.2016.06.012. Epub 2016 Jun 15.
• [61] Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravis.Orphanet J Rare Dis. 2019 Jan 29;14(1):24. doi: 10.1186/s13023-019-1003-y.
• [62] Silencing of Dok-7 in Adult Rat Muscle Increases Susceptibility to Passive Transfer Myasthenia Gravis.Am J Pathol. 2016 Oct;186(10):2559-68. doi: 10.1016/j.ajpath.2016.05.025.
• [63] CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis.J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):241-2. doi: 10.1136/jnnp.2008.149336.
• [64] Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.J Neuroimmunol. 2014 Nov 15;276(1-2):150-8. doi: 10.1016/j.jneuroim.2014.09.013. Epub 2014 Sep 19.
• [65] Thymoma-associated myasthenia gravis: On the search for a pathogen signature.J Autoimmun. 2014 Aug;52:29-35. doi: 10.1016/j.jaut.2013.12.018. Epub 2014 Jan 17.
• [66] Molecular profiling of thymoma with myasthenia gravis: Risk factors of developing myasthenia gravis in thymoma patients.Lung Cancer. 2020 Jan;139:157-164. doi: 10.1016/j.lungcan.2019.11.007. Epub 2019 Nov 15.
• [67] HLA and Singaporean Chinese myasthenia gravis.Int Arch Allergy Immunol. 1993;101(2):119-25. doi: 10.1159/000236508.
• [68] IFNA-AS1 regulates CD4(+) T cell activation in myasthenia gravis though HLA-DRB1.Clin Immunol. 2017 Oct;183:121-131. doi: 10.1016/j.clim.2017.08.008. Epub 2017 Aug 16.
• [69] Whole-exome sequencing reveals a rare interferon gamma receptor 1 mutation associated with myasthenia gravis.Neurol Sci. 2018 Apr;39(4):717-724. doi: 10.1007/s10072-018-3275-8. Epub 2018 Feb 13.
• [70] Non-synonymous single nucleotide polymorphisms in genes for immunoregulatory galectins: association of galectin-8 (F19Y) occurrence with autoimmune diseases in a Caucasian population.Biochim Biophys Acta. 2012 Oct;1820(10):1512-8. doi: 10.1016/j.bbagen.2012.05.015. Epub 2012 Jun 7.
• [71] Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy.J Neuroimmunol. 2018 Apr 15;317:100-102. doi: 10.1016/j.jneuroim.2018.01.011. Epub 2018 Feb 1.
• [72] The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis.J Cell Biochem. 2019 Apr;120(4):5542-5550. doi: 10.1002/jcb.27838. Epub 2018 Oct 26.
• [73] Acetylcholine receptor alpha-subunit and myogenin mRNAs in thymus and thymomas.Am J Pathol. 1995 Jun;146(6):1320-4.
• [74] Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration.Acta Neuropathol. 2017 Dec;134(6):869-888. doi: 10.1007/s00401-017-1754-2. Epub 2017 Jul 29.
• [75] Alternatively spliced transcripts of the thymus-specific protease PRSS16 are differentially expressed in human thymus.Genes Immun. 2005 Feb;6(1):1-7. doi: 10.1038/sj.gene.6364142.
• [76] Different molecular expression in thymoma with ocular or generalized myasthenia gravis.J Neurol Sci. 2012 Feb 15;313(1-2):27-31. doi: 10.1016/j.jns.2011.09.037. Epub 2011 Oct 13.
• [77] MicroRNA-653 Inhibits Thymocyte Proliferation and Induces Thymocyte Apoptosis in Mice with Autoimmune Myasthenia Gravis by Downregulating TRIM9.Neuroimmunomodulation. 2019;26(1):7-18. doi: 10.1159/000494802. Epub 2019 Jan 31.
• [78] Autoimmunogenic HLA-DRB1*0301 allele (DR3) may be distinguished at the DRB1 non-coding regions of HLA-B8,DR3,Dw24 and B18,DR3,Dw25 haplotypes.Mol Immunol. 1991 Jan-Feb;28(1-2):189-92. doi: 10.1016/0161-5890(91)90105-s.
• [79] Complement C2 siRNA mediated therapy of myasthenia gravis in mice.J Autoimmun. 2013 May;42:94-104. doi: 10.1016/j.jaut.2013.01.003. Epub 2013 Feb 12.
• [80] Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492.
• [81] Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis.J Neuroimmunol. 2016 Dec 15;301:30-34. doi: 10.1016/j.jneuroim.2016.10.011. Epub 2016 Nov 9.
• [82] Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?.Oncotarget. 2017 Sep 8;8(56):95432-95449. doi: 10.18632/oncotarget.20731. eCollection 2017 Nov 10.
• [83] PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis.Med Sci Monit. 2015 Aug 30;21:2567-71. doi: 10.12659/MSM.894307.
• [84] Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report.Front Neurol. 2019 Jul 16;10:770. doi: 10.3389/fneur.2019.00770. eCollection 2019.
• [85] Genetic basis of myasthenia gravis - a comprehensive review.J Autoimmun. 2014 Aug;52:146-53. doi: 10.1016/j.jaut.2013.12.001. Epub 2013 Dec 19.